BDNF and bone cancer: Then, FSLLRY-NH2 (10 μg, from day3 to day 15), the antagonist of PAR2, was daily delivered via the intrathecal catheter to determine its effect on BDNF function, glutamatergic strength and pain behavior in the rats with bone cancer.